Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Feb 13, 2023 6:32pm
406 Views
Post# 35284084

What to use next?

What to use next?

The Basics of Switching HIV Treatment

The Basics of Switching HIV Treatment

"When switching due to virological failure, resistance tests can show which drugs are not working and which alternative antiretrovirals are likely to work best. Switching treatment is more challenging for people who have already used many drugs and have developed resistance to multiple medications (known as multidrug-resistant HIV).

 

Ideally, a new regimen should contain at least two, preferably three, fully active drugs, but this is not always possible. Some people may be able to add novel antiretrovirals that work in different ways, such as the monoclonal antibody entry inhibitor Trogarzo (ibalizumab) or the twice-yearly injectable capsid inhibitor Sunlenca (lenacapavir). Another option is joining a clinical trial, but currently, there are few experimental antiretrovirals in the pipeline.

 

Modern antiretrovirals are more potent, better tolerated, less likely to lead to drug resistance and more convenient than older meds. With the newest drugs, even people who have been living with HIV for years and have highly resistant virus can usually find a regimen that keeps their HIV in check."

 

<< Previous
Bullboard Posts
Next >>